Lviv clinical bulletin 2017, 1(17): 12-15

https://doi.org/10.25040/lkv2017.01.012

The Content of Vasodilation Factors in Blood Serum at Different Levels of Systolic- Diastolic Dysfunction of Left Ventricular with Stable Stenocardia Complicated by Heart Failure

Posted onAuthorAdminЗалишити коментар / Leave a comment

V. Denesyuk, N. Muzyka

National Pirogov Memorial Medical University, Vinnytsya

Introduction. Congestive heart failure (CHF) is still the most topical medical­and­social problem all around the world. It is the most common and life­threatening disease of the cardiovascular system, resulting in permanent disability, leads to permanent disability, and significant reduction of life in longevity and quality.

Objective. To find out the the level of vasodilation factors in blood serum at different levels of systolic­diastolic dysfunction of left ventricular in patients with stable angina of II­III functional class, complicated by the heart failure with reduced fraction of left ventricular ejection.

Materials and methods. To study the goal was conducted a full clinical examination of 47 patients with stable angina of II­III functional classes (FC), complicated by the heart failure (HF) І­ІІІ FC with LV EF ≤ 45.0 % (31 men and 16 women, the average age of the patients was 66.00 ± 1.50 years). In addition to complex clinical­laboratory and instrumental investigations that meet modern requirements, patients underwent quantification of markers vasodilation ­ nitrites (NO2­) and nitrate (NO3­), eNOS. ENOS content in blood serum was determined by ″Nitric Oxide Synthase 3, Endothelial (еNOS) Human ELISA Kit″ (Cloud­Clone Corp, USA).

Results and discussion. Analysis of vasodilation levels at different types of diastolic dysfunction (DD) LV in­ dicates that at the delayed relaxation the average level of eNOS was 498.55 ± 42.80 pg/ml, which is significantly higher than restrictive type of DD LV (p < 0.01). In pseudonormal type DD LV the average level of eNOS was 407.24 ± 54.59 pg/ml, which is significantly higher than restrictive type of  DD LV (p < 0.05).

Conclusions. In patients with stable angina of II­III FC complicated by the systolic heart failure with reduced ejection fraction of left ventricular, in the majority was determined II (moderate) degree of systolic dysfunction of left ventricular. Carried correlation analysis between the levels of eNOS in serum and ejection fraction of left ventricular in examined patients with stable angina of II­III FC complicated by the heart failure with the reduced ejection fraction of left ventricular, led to the establishment of a direct correlation of weak force. In patients with stable angina of II­III FC complicated by the heart failure with the reduced ejection fraction of left ventricular were mainly determined pseudonormal and restrictive types of diastolic dysfunction of left ventricular. In examined patients is observed trend to reduction of vasodilating factors (such as eNOS, nitrites and nitrates) on the progression of stages of systolic­diastolic dysfunction of the left ventricular.

References

  1. Ageev F. The role of endothelial dysfunction in devel opment and progression cardiovascular diseases. Heart Failure. 2004;4(1):21-22. (Ukrainian).
  2. Voronkov L. Comparative characteristics of the main clinical and demographic and quality of life in patients with chronic heart failure of ischemic origin of left ventricular systolic dysfunction and with preserved left ventricular ejection fraction. Ukrainian Journal of Cardiology. 2012;4:65-70. (Ukrainian).
  3. Denesyuk V. Chronic heart failure. Standards for the diagnosis, treatment and prevention of the criteria of evidencebased medicine. Therapeutic Ukrainian Magazine. 2008;2:106-113. (Ukrainian).
  4. Denesyuk O, Denesyuk V. Dynamics degrees remodeling and systolicdiastolic left ventricular dysfunction in unstable angina influenced the optimal longterm treatment. Herald Problems of Biology and Medicine. 2015;1(2):121-126. (Ukrainian).
  5. Zharynova V. Modern opportunities optimization endothelium tread therapy in patients with CHF (focus on eNOS). Heart Failure. 2013;3:46-53. (Ukrainian).
  6. Zaremba E, Besedina A. The role of the family physician in the prevention of cardiovascular disease. Family Medicine. 2012;1:48-50. (Ukrainian).
  7. Menshikov V, editor. Laboratory Methods in clinic: Manual. Moskow: Medicine, 1987. 368 p. (Russian).
  8. Kapelko V. Diagnostic dysfunction. Cardiology. 2011;1:79-90. (Russian).
  9. Korenman I. Methods for determination of organic compounds. Moskow: Chemistry, 1975. 360 p. (Russian).
  10. Mandate of the Ministry of Health of Ukraine from 2016 Mar 02 N 152 ″On approval of the introduction of medical and technological documents for standardization of care in stable coronary heart disease″. News of Medicine and Pharmacology in Ukraine. 2016;572:26-60. (Ukrainian).
  11. Denesyuk O, Denesyuk V, Afanasyuk O et al., inventor, assignee. The method of diagnosis degrees of left ventricular hypertrophy in patients with cardiovascular diseases. Patent Ukraine N 86395. 2013 Dec 25 (Ukrainian).
  12. Svischenko E, Matova E, Mishchenko L. LV diastolic dysfunction in hypertensive patients: correction with valsartan. Arterial Hypertension. 2012;2:39-46.
  13. Aljaroudi W, Alraies MC, Halley C, Rodriguez L, Grimm RA, Thomas JD et al. Inpact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction. Circulation. 2012;126(6):782-788. https://doi.org/10.1161/CIRCULATIONAHA.111.066423